Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Earnings Data
Report Date
Aug 01, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.88Last Year’s EPS
-0.58Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 09, 2025
|% Change Since: -1.95%
|Next Earnings Date:Aug 01, 2025
Earnings Call Sentiment|Positive
Despite market challenges and strategic pausing of the TIC2 program, Kymera Therapeutics, Inc. demonstrated strong financial health and significant advancements in their pipeline, highlighted by the launch of new programs and promising preclinical results.Company Guidance
During the call, Kymera Therapeutics, Inc. provided guidance on their strategic focus and upcoming milestones. They reported $775 million in cash as of the end of the first quarter of 2025, extending their financial runway into the first half of 2028. The company has introduced IRAF5 as its latest high-value immunology program, alongside their existing STAT6 and IRAK4 programs. They announced that five new molecules have been brought into the clinic since 2020, with a goal to have ten by 2026. Over 300 subjects have been dosed across their pipeline, achieving more than 90% protein degradation in trials. The call also announced a strategic decision not to advance the TIC2 degrader into clinical development, reallocating resources to focus on STAT6 and IRAF5, aiming for clinical data readouts for STAT6 in June and the fourth quarter of 2025. The company expects to start a Phase 1 trial for IRAF5 in early 2026, with ongoing efforts to demonstrate best-in-class efficacy and safety profiles across their programs.Strong Financial Position
Kymera Therapeutics, Inc. reported having $775 million in cash reserves, extending their runway into the first half of 2028.
Promising Pipeline Advancements
The company has progressed five new molecules into the clinic since 2020, with plans to deliver 10 molecules by 2026. Notably, they achieved more than 90% degradation in preclinical studies across programs with the desired efficacy and safety profile.
Launch of IRAF5 Program
Kymera Therapeutics, Inc. introduced KT579, their first-in-class IRAF5 degrader, which has shown promising preclinical results in autoimmune diseases like lupus and RA.
STAT6 Degrader Progress
The company is advancing KT621, their oral STAT6 degrader, demonstrating potential to provide dupilumab-like efficacy with the convenience of an oral drug.
Preclinical Milestone Achievement
Kymera achieved a preclinical milestone in the IRAK4 program resulting in a $20 million payment expected in Q2 2025.
KYMR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KYMR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 09, 2025 | $30.77 | $30.07 | -2.27% |
Feb 27, 2025 | $35.36 | $30.25 | -14.45% |
Oct 31, 2024 | $47.67 | $46.17 | -3.15% |
Aug 07, 2024 | $41.42 | $40.31 | -2.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kymera Therapeutics (KYMR) report earnings?
Kymera Therapeutics (KYMR) is schdueled to report earning on Aug 01, 2025, TBA Not Confirmed.
What is Kymera Therapeutics (KYMR) earnings time?
Kymera Therapeutics (KYMR) earnings time is at Aug 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KYMR EPS forecast?
KYMR EPS forecast for the fiscal quarter 2025 (Q2) is -0.88.